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Abstract
Objective—To systematically review the published literature in order to estimate the incidence 
and describe the variability of human papillomavirus (HPV) infection in women following 
treatment for cervical neoplasia.
Methods—Several scientific literature databases (e.g. PubMed, ISI Web of Science) were 
searched through January 31, 2012. Eligible articles provided data on (i) baseline HPV infection 
status within 6 months prior to or at time of treatment (pre-treatment); and (ii) HPV test results for 
women's first visit after treatment occurring within 36 months (post-treatment). We abstracted and 
summarized the post-treatment incidence of newly detected HPV genotypes that were not present 
at pre-treatment, overall and stratified by study and other population characteristics.
Results—A total of 25 studies were included, reporting post-treatment HPV incidence in nearly 
2000 women. Mean patient age ranged from 31 to 43 years (median 36). Most studies used 
cervical exfoliated cell specimens to test for HPV DNA (n = 20; 80%), using polymerase chain 
reaction (n = 21; 84%). Cervical neoplasia treatment included loop electrical excision procedure (n 
= 11; 44%); laser conization (n = 2; 8%); laser ablation, surgical conization, cryotherapy, alpha-
interferon (n = 1; 4% each); or multiple treatment regimens (n = 8; 32%). Follow-up times post-
treatment ranged from 1.5 to 36 months (median 6). More than half of studies (n = 17; 68%) 
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estimated the incidence of any HPV type following treatment, while 7 (28%) focused specifically 
on high-risk (HR) HPV. HPV incidence after treatment varied widely, ranging from 0 to 47% 
(interquartile range: 0%-15%) in up to 3 years of follow-up after treatment. Lower HPV incidence 
was observed among studies that included relatively younger women, used laser conization, 
focused on HR-HPV rather than overall HPV infection, and had a lower proportion of recurrent 
cervical disease.
Conclusions—These modest summary incidence estimates from the published literature can 
guide clinicians, epidemiologists and health economists in developing best practices for post-
treatment cervical cancer prevention.
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Introduction
Cervical cancer remains a leading cause of morbidity and mortality in women worldwide 
[1,2]. It is caused by the acquisition and persistence of high-risk (oncogenic) types of human 
papillomavirus (HR-HPV) infection and the subsequent malignant transformation of cervical 
epithelial cells [3]. To prevent progression of these cervical precancerous lesions to invasive 
cancer, women with cervical intraepithelial neoplasia (CIN) grade 2/3 are commonly treated 
using ablative and excisional treatment modalities such as laser ablation, loop electrical 
excision procedure (LEEP), cryotherapy, and cold-knife conization [4]. Women previously 
treated for CIN 2/3 and those with HR-HPV infections post-treatment have an increased risk 
of subsequent high-grade neoplasia and invasive cervical cancer as compared with women 
in the general population [5–8].
Recurrent CIN may result from the inadequate treatment of precancerous cervical lesions or 
treatment failure, re-infection with an HR-HPV type, incomplete removal of latent HPV 
infections or long-term persistence of HR-HPV infections not associated with the previously 
treated cervical lesion [9–11]. Therefore, continued monitoring of women following cervical 
treatment is currently recommended. American Society for Colposcopy and Cervical 
Pathology (ASCCP) guidelines recommend follow-up HPV testing at 6 to 12 months for 
women treated for CIN 2/3 [4], since women at highest risk for recurrent cervical disease are 
those with positive post-treatment HPV test results [12]. Post-treatment screening with 
cytology alone, or in combination with colposcopy, at 6-month intervals are alternative 
recommended approaches [4].
Despite the growing use of HPV testing for post-treatment follow-up, there are currently no 
summary data on the burden of newly detected HPV infections following treatment for CIN. 
Therefore, we conducted a systematic literature review to describe study- and population-
specific factors that may contribute to the magnitude and variability of estimates of HPV 
incidence following cervical treatment. The focus of this review is on newly detected HPV 
genotypes that were not detected prior to or at cervical treatment, which most likely 
represent newly acquired or newly reactivated latent infections, as opposed to type-specific 
reinfection or infections associated with incomplete excision of precancerous lesions.
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We searched PubMed, EMBASE, ISI Web of Science, Cochrane Library, and Cumulative 
Index to Nursing and Allied Health Literature (CINAHL) through January 31, 2012 without 
date or language restrictions to identify peer-reviewed articles reporting incident HPV data 
from women treated for HPV-associated cervical neoplasia. Our keyword search was 
designed in consultation with a reference librarian at the University of North Carolina 
Health Sciences Library. The search contained a combination of terms including HPV (i.e., 
HPV, papillomaviridae, human papillomavirus, papillomavirus infection), cervical neoplasia 
(i.e., cervical neoplasms, cervical cancer, cervical neoplasia, cervical intraepithelial 
neoplasia), occurrence (i.e., incidence, newly detected, persistence, clearance, duration, 
epidemiology, cohort study), and treatment- or screening-related terms (i.e., post-treatment, 
follow-up, over time, long-term, therapeutics, cryotherapy, LEEP, laser, and colposcopy).
Citations were imported into a reference managing software program (EndNote X5, 
Thomson Reuters) and duplicate citations were removed. Backward citation tracking was 
used to ensure appropriate keywords were selected for the literature search and resulted in 
modification of these terms followed by an updated search of databases. Titles and abstracts 
of search results were selected for full-text evaluation with respect to two inclusion criteria: 
(i) women receiving treatment for cervical neoplasia; and (ii) post-treatment HPV 
acquisition data.
Eligibility criteria
Eligible articles provided data on HPV infection within 6 months prior to or at time of 
treatment (i.e., pre-treatment time point) and incident HPV detection occurring during 
follow-up, with the first follow-up visit with HPV test results occurring within the first 36 
months post-treatment. Thus, it must have been clear in the article that an HPV infection 
was newly detected in the post- compared to pre-treatment period. The majority of results 
were type-specific, based on HPV genotyping assays, although four studies used non-type-
specific Hybrid Capture II among pre-treatment HPV-negative women, where a positive 
result would indicate a new HPV type.
Studies of women with human immunodeficiency virus (HIV) infection were only included 
if HPV data were available on the HIV-negative subpopulation. Articles that did not state 
HIV serostatus were assumed to be HIV-negative and thus included. Studies that included 
women treated for invasive cervical carcinoma (ICC) in their study population were 
included only if HPV data were also available on the subset of women treated for earlier 
stages of CIN. Studies that tested for cervical HPV infections using polymerase chain 
reaction (PCR) and hybrid capture DNA were included. HPV serology-only studies and 
studies that included only anal, vulvar or labial specimens were excluded. Studies that 
reported exclusively on men, oral HPV infection or oral cancer, animal studies, or 
simulation studies were ineligible.
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From articles meeting our inclusion criteria, we abstracted data on study characteristics, 
participants, cervical treatment type, and pre- and post-treatment HPV infection and testing. 
Study characteristics included journal of publication, publication date, study dates, study 
design, geographic region, and sample size. Participant characteristics included age and 
population description (e.g., clinical patients, population-based screening participants). 
Treatment characteristics included methods used to grade cervical lesions (cytology vs. 
histology), grade of cervical lesions at time of treatment (e.g., CIN 1, CIN 2, and CIN 3), 
and treatment type. HPV infection and testing characteristics included HPV specimen type 
(cervical cells vs. biopsy), HPV testing method (PCR vs. hybrid capture 2), specific HPV 
types tested, HPV testing time relative to treatment, pre-treatment HPV prevalence in the 
study population, and if applicable, pre-treatment HPV types in HPV-positive women. Post-
treatment characteristics included unit of analysis for incidence results (i.e., women, 
infections), follow-up HPV testing intervals, number of incident HPV infections reported, 
post-treatment incident HPV types, and stage of post-treatment cervical disease. All data 
were independently double-abstracted to ensure data accuracy.
Definition of HPV incidence measures
Incident HPV infections were defined as detection of a new genotype after treatment for 
cervical neoplasia that was not present before or at the time of treatment. For example, a 
woman who was HPV 18 positive at pre-treatment, received treatment, and tested positive 
for HPV 16 following treatment would be classified as having a post-treatment incident 
HPV 16 (type-specific) infection. Among populations of women with a completely HPV-
negative result before or at the time of treatment, incidence was defined as any positive HPV 
test result at a post-treatment visit.
HPV incidence estimation
To estimate the incidence of HPV infection in women following treatment for cervical 
neoplasia, the number of women with newly detected (type-specific) HPV infections and the 
number of women in each subgroup were used to calculate the HPV incidence with 
corresponding Mid-P exact 95% confidence limits for each study [13]. Most studies report 
HPV incidence measured at a specific time point (incidence proportion); however if only 
HPV incidence up to and including a specific time point (cumulative incidence) estimates 
were reported, these were abstracted. Incidence estimates were categorized by pre-treatment 
HPV status in the study population: (i) a population or subgroup of women who all tested 
negative for all HPV prior to or at the time of treatment (pre-treatment HPV negative); (ii) a 
population or subgroup where some women tested HPV-positive and some tested HPV-
negative prior to or at the time of treatment (mixed HPV pre-treatment status); and (iii) a 
population or subgroup of women who all tested positive for HPV prior to or at the time of 
treatment (pre-treatment HPV positive).
HPV incidence estimates were graphically displayed according to study and population-
specific characteristics and corresponding study follow-up time. HPV incidence estimates 
calculated using less than 5 women were not graphically displayed, although they are 
presented in the tables.
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Of the 2549 abstracts identified, 166 full-text articles were screened, and a total of 26 studies 
met the inclusion criteria (Fig. 1). One study [14] included cohorts previously described in 
two other eligible studies [7,15]. One eligible study was excluded, as it reported HPV 
incidence rate ratios in treated compared to untreated women, but did not report HPV 
incidence data for treated women alone [16].
The 25 included studies provided estimates on post-treatment HPV incidence in nearly 2000 
women. Most studies were conducted in Europe (n = 14; 56%) and Asia (n = 5; 20%), with 
8% (n = 2) from South America and 4% (n = 1) each from North America, Africa, the 
Middle East, and multiple regions (Table 1). Eighty-eight percent (n = 22) of eligible studies 
were cohort studies, though two randomized controlled trials [15,17] and one case–control 
study [18] were also included. Study participants were recruited primarily through clinical 
settings (n = 19; 76%) although 16% (n = 4) included women referred from population-
based screening programs. Mean patient age ranged from 31 to 43 years (median 36), and 
mean age was not reported for two studies [19,20]. Most studies (n = 20; 80%) used cervical 
cell specimens as opposed to biopsy specimens to test for HPV DNA, and 84% (n = 21) of 
studies used PCR to detect HPV infection. Sixty percent (n = 15) provided HPV incidence in 
populations entirely HPV positive at the time of treatment, 48% (n = 12) of studies provided 
an estimate of HPV incidence in a population that was completely HPV negative at the time 
of cervical treatment, and 60% (n = 15) reported estimates in a population with pre-
treatment mixed HPV status.
The majority of studies (n = 24; 96%) used histology to diagnose cervical neoplasia (Table 
1). While 48% (n = 12) provided estimates of HPV incidence in populations treated for CIN 
2/3 and 32% (n = 8) had populations treated for CIN 1/2/3, other studies provided estimates 
in women with specifically CIN 1 (n = 2, 8%), CIN 2 (n = 3, 12%), or CIN 3 (n = 6, 24%). 
One study treated women who had acetowhite lesions detected using visual inspection with 
acetic acid (VIA) [17]. There was heterogeneity in treatment type among the studies: 44% (n 
= 11) used LEEP; 8% (n = 2) used laser conization; 4% (n = 1) each used laser ablation, 
surgical conization, cryotherapy and alpha-interferon; and 32% (n = 8) used multiple 
treatment regimens.
Post-treatment HPV incidence
Follow-up time for measuring HPV incidence ranged from 1.5 to 36 months (median 6) 
following cervical treatment (Table 2). Sixty-eight percent (n = 17) of studies estimated any-
HPV type incidence following treatment for cervical neoplasia, while 28% (n = 7) of studies 
focused specifically on HR-HPV infection. In most cases, studies reported the HPV 
incidence proportion at the specific time point, however, three studies reported the 
cumulative incidence of HPV over a period of time [17,21,22]. Some studies solely provided 
an HPV incidence estimate for their entire study population, while other studies provided 
sufficient data to calculate separate HPV incidences for different subgroups, such as pre-
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treatment HPV negative patients, pre-treatment HPV positive patients, those with particular 
stages of pre-treatment cervical disease, and those with residual or recurrent disease.
Estimates of HPV incidence for whole study populations and reported subpopulations are 
presented in Table 2. In 14 studies, HPV incidence was 0% over follow-up periods ranging 
from 2 to 31.8 months post-treatment among subpopulations of women who were pre-
treatment HPV negative [6,23–28], of mixed HPV status [7,19,28–30], or HPV positive 
[20,28,30–32]. Only two small subpopulations of women, both of which were pre-treatment 
HPV negative, reported HPV incidences of 100% at 3 months [20] and at 4 months [22] 
post-treatment. Of the 25 total studies, 16 (64%) specifically reported the incidence of HPV 
types 16 and 18 (see Supplemental Table 1), finding only 3 incident cases of HPV 16/18 
among 32 women negative for HPV 16/18 at the pre-treatment visit. HPV 16/18 incidence 
ranged from 0% [6,7,19,23,28,30] to 29% [20] among populations of women with mixed 
pre-treatment HPV statuses and from 0% [7,20,23,28,30–32] to 20% [20,32] among pre-
treatment HPV-positive women over 2–19 months of post-treatment follow-up.
Age-stratified post-treatment HPV incidence
Among studies with a mean patient age at treatment of 30–34 years, HPV incidence 
estimates were fairly low up to 19 months post-treatment, with estimates ranging from 0% to 
5% (Fig. 2). There was more variation at 24 months post-treatment: one study among 
women with pre-treatment mixed HPV status found an HPV incidence of 5% [14], while 
another found HPV incidence of 30% among pre-treatment HPV negative women and 47% 
among pre-treatment HPV positive women [21].
In studies with a mean patient age of 35–39 years, HPV incidence ranged from 0% to 18% 
at 2 to 6 months post-treatment and from 0% to 24% >6 to 35 months post-treatment. Of the 
three studies where the mean age was 40–44 years and HPV incidence estimates included at 
least 5 women, one study reported no incident HPV infections [28], one reported HPV 
incidence of 24% at 6 months [18], and another found an increasing cumulative HPV 
incidence over time from 6% at 6 months to 13% at 36 months post-treatment [17].
Treatment-stratified post-treatment HPV incidence
The majority of HPV incidence estimates were among women treated for cervical neoplasia 
using LEEP (Fig. 3), where HPV incidence ranged from 0% to 18% at 2 to 6 months post-
treatment and 0% to 24% at >6 to 35 months post-treatment. Among women treated with 
laser conization, HPV incidence appeared relatively lower: one study found no incident 
HPV infections at 3, 6, or 12 months post-treatment [26], and another found HPV incidences 
of 1% in pre-treatment HPV positive women and 7% in pre-treatment HPV negative women 
after a longer follow-up duration of 35 months [33]. Only one study used laser ablation, and 
found an incidence of 15% in all women and 0% in pre-treatment HPV positive women at 3 
months [20]. One study that used surgical conization found cumulative HPV incidences 
ranging from 6% at 6 months to 13% at 36 months [17], while another that used alpha-
interferon found no incident HPV infections at 2 months [19]. Studies that utilized multiple 
treatment modalities reported a wider range of HPV incidences, ranging from 0% to 24% at 
2 to 6 months and 0% to 47% at 6 to 24 months. The three highest HPV incidence estimates 
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(24% at 6 months, 30% at 24 months, 47% at 24 months) were all found by studies using 
multiple treatment regimens. Stratification by cervical disease status (CIN 1/2/3 vs. CIN 2/3) 
did not produce any clear patterns over follow-up time (Supplemental Fig. 1). However, 
women with recurrent cervical disease tended to have higher HPV incidence, as opposed to 
total study populations, ranging from 0% to 29% at 2 to 6 months and 3% to 47% at 14 to 24 
months (Supplemental Fig. 2).
Post-treatment HPV incidence stratified by HPV type
Most studies measured any incident HPV type that was included in the diagnostic assay used 
(Fig. 4). However, incidence estimates from a subset of studies specific to HR-HPV (n = 7), 
which varied in number and genotypes included in the HR-HPV subset, tended to be 
somewhat lower than those including all HPV types as would be expected, ranging from 0% 
to 24% at 3 to 11 months; and 2% to 21% at 12 to 36 months. One study examined only 
HPV types 6 and 16 and found noincident infections over two months of follow-up [19].
Discussion
Post-treatment HPV testing as confirmation of successful cervical treatment may allow 
women to return to routine, extended cervical cancer screening intervals. However, it is 
important to distinguish between and understand differences in the incidence and natural 
history of newly detected HPV genotypes compared to recurrent detection of lesion-
associated HPV genotypes. Little is known about the frequency of newly detected HPV 
genotypes following treatment for cervical precancer and cancer, yet these estimates are 
important for determining the optimal use and interpretation of post-treatment HPV 
screening results, and may also aid in determining whether vaccination may have any 
benefit in these women. In this systematic literature review summarizing 25 studies with 
post-treatment HPV data on over 2000 women, most studies reported low, although non-
negligible estimates of HPV incidence even over relatively short periods of follow-up. 
Estimates of post-treatment HPV incidence varied by patient and treatment-related variables. 
Specifically, HPV incidence estimates appeared lower among populations of women treated 
with laser conization compared to those treated with LEEP, relatively younger aged women, 
and among women without recurrent cervical disease. Women with pre-treatment HPV 
infections had higher incidence of post-treatment HPV infections compared to women who 
were HPV negative at or before treatment.
Women who have previously developed cervical disease may be more likely to develop 
subsequent cervical precancer and cancer than women without previous disease and 
treatment [34]. Although a substantial proportion of post-treatment precancer and cancers 
likely result from incomplete excision of the lesion or persistence of the lesion-associated 
HPV type, women are also at risk of developing a second cervical precancer due to the 
acquisition and persistence of newly acquired HPV types. Unfortunately, data on type-
specific HPV infection associated with development of cervical disease after treatment are 
limited [35–38] and most studies have focused on, or did not distinguish between, recurrent 
or residual cervical disease outcomes rather than newly acquired HPV associated-lesions. In 
addition, the natural history of newly detected HPV infections likely differ from persistent 
Rositch et al. Page 7













post-treatment infections and may require a longer follow-up period to assess true risk of 
disease. Thus, in this review, we take the first step to summarize the burden of newly 
acquired HPV genotypes after cervical treatment. Our review indicates that in studies with 
up to 36 months of follow-up after treatment, HPV incidence ranges widely from 0% to 
47%, with most published estimates ranging from 0% to 15%. These incidence estimates 
suggest a need to better understand the risk and timing of new high-grade cervical precancer 
following treatment for cervical disease.
Our summary of newly detected HPV 16 and 18 after treatment (Supplemental Table 1) are 
valuable as the research continues regarding the utility of HPV vaccination at the time of 
treatment. Although this literature review clarifies that the frequency of incident HPV-16/18 
infections is non-negligible among women post-treatment, they are observational data which 
give no indication of the efficacy of HPV vaccination post-treatment. However, recent 
evidence from a retrospective analysis of a subset of young women aged 15–26 years from 
two randomized control trials of prophylactic HPV vaccination [39], and from men treated 
for high-grade anal disease [40], highlight the potential for HPV vaccination to prevent 
subsequent disease after treatment. In a prospective study of vaccination after LEEP, the risk 
of recurrent disease was significantly higher in the unvaccinated women (adjusted hazard 
ratio: 2.84 and 95% confidence interval: 1.34–6.04) [41]. Previous studies suggest that 
vaccination provides no therapeutic benefit for those already infected with HPV vaccine 
types so it is likely that any observed benefit from post-treatment vaccination would be due 
to prevention of incident HPV infections after treatment. These incident infections may 
reflect newly reactivated latent HPV rather than truly new HPV infections, particularly in 
older women [42].
The mean ages of the study populations in this review ranged from 31 to 43 years, with a 
median of 36 years. Patterns of newly detected HPV genotypes after cervical treatment seem 
to indicate a slight trend of lower incidence in younger aged populations, in contrast to the 
higher HPV incidence observed in younger compared to older women in the general 
population [43,44]. Explanations for these observed differences are not clearly understood, 
but could possibly be attributable to immunological differences between younger and older 
women. Although this review includes data on women aged 18 to 82 years of age, data were 
extremely limited from populations of women with a mean age of 40 years and older, with 
only 3 available studies. Thus, additional literature is needed regarding post-treatment HPV 
incidence in populations of perimenopausal and older women.
A recent meta-analysis found that the sensitivity of HR-HPV testing was higher than 
cytology at detecting high-grade post-treatment disease, but with a slightly lower 
corresponding specificity [45]. Data from cost-effectiveness analysis suggests that HPV 
testing combined with cytology under a select protocol, as opposed to cytology only, would 
reduce the cost and number of colposcopies post-treatment [46]. Together, these studies 
support inclusion of HR-HPV testing in screening algorithms after cervical treatment. 
However, previous cost-effectiveness analyses or studies of sensitivity, to our knowledge, 
have not examined the role of HPV genotyping to distinguish between HR-HPV infections 
that were present pre-treatment versus those that were newly detected HPV types, as we 
have done in this review. If the risk of developing cervical precancer or cancer after 
Rositch et al. Page 8













treatment associated with persistent pre-treatment HPV genotypes differs from newly 
detected genotypes [35], then more data are needed to determine if type-specific HPV 
testing could potentially improve the sensitivity and specificity of HPV detection in 
screening for post-treatment cervical disease.
Strengths of our study include a systematic approach, with a large sample size of women 
with data on HPV incidence. Given a priori evidence regarding the potential heterogeneity 
of study and population characteristics on the natural history of HPV infection, we did not 
conduct a statistical meta-analysis of HPV incidence estimates post-treatment. Furthermore, 
twelve studies included a relatively small number of women (Table 2) with HPV-negative 
CIN pre-treatment (one study specifically focused on HPV-negative, VIA-positive women 
[17]). Since these cases likely differ, for example representing regressing lesions, from those 
with detectable HPV, we present stratified results. In addition, it is possible that HPV 
detection prior to or at the time of treatment missed an HPV genotype that was actually 
present or recently became undetectable, in which case, its detection post-treatment is not 
truly new. This potential source of misclassification may be most evident in the cases of 
HPV-negative CIN. In addition, we did not systematically assess HPV serological status of 
women, an important indicator of previous HPV infection.
The reported HPV incidence estimates are absolute measures of frequency and do not 
provide specific information regarding statistical or causal relationships among factors 
which may influence post-treatment HPV incidence. Because there were small numbers of 
women in many of the subgroups, HPV incidence estimates are relatively unstable for 
several studies included in this review, as indicated by relatively wide confidence limits. 
However, clinically relevant trends were consistently observed within large studies, 
including an increase in HPV incidence over follow-up time [17,22]. Patterns were also 
observed across studies, such as the low incidence of HPV in women treated by laser 
conization [26,33] relative to other treatment modalities.
By providing summaries of post-treatment HPV incidence by key factors, we aim here to 
inform clinicians, researchers, and health economists about the burden of newly detected 
HPV infections among women following treatment for cervical disease. The current ASCCP 
recommendation following treatment for CIN 2/3 in women 25 years and older is the use of 
HPV testing with cytology (cotesting) at 12 and 24 months[47]. As HPV genotyping assays 
become increasingly utilized in clinical practice, further research will be needed to 
determine whether type-specific HPV results can improve the identification of women most 
at risk of developing cervical disease after treatment since this systematic review highlights 
that new HPV infections are a potential source for future disease risk after treatment for 
cervical precancer and cancer.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Women with post-treatment HPV have a higher risk of subsequent cervical 
precancer.
• This review of post-treatment HPV included nearly 2000 women from 25 
studies.
• Post-treatment HPV incidence ranged from 0 to 47% in up to 3 years of follow-
up.
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Identification and selection of eligible studies.
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Post-treatment HPV incidence, stratified by mean patient age at treatment.
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Post-treatment HPV incidence, stratified by cervical neoplasia treatment type.
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Post-treatment HPV incidence, stratified by incident HPV types reported.
Rositch et al. Page 18

























Rositch et al. Page 19
Table 1
Descriptive characteristics of 25 studies with human papillomavirus incidence data following treatment for 
cervical neoplasia.
No. of studies (%) References
Study characteristics
Study design
 Cohort 22 (88) [6,7,14,19–33,48–51]
 Randomized controlled trial 2 (8) [15,17]
Case–control 1 (4) [18]
Study region
 Europe 14 (56) [7,14,15,18,19,21,22,26,29,31,33,48–50]
 Asia 5 (20) [6,23,25,28,51]
 South America 2 (8) [24,32]
 North America 1 (4) [20]
 Africa 1 (4) [17]
 Middle East 1 (4) [30]
 Multi-regiona 1 (4) [27]
Population characteristics
Study population
 Clinical patients 19 (76) [6,7,14,19–21,23–28,30–32,48–51]
 Screening program referrals 4 (16) [18,22,29,33]
 Randomized controlled trial participants 2 (8) [15,17]
Mean age of study populations in yearsb
 30–34 6 (24) [7,14,21,24,31,32]
 35–39 13 (52) [6,15,22,23,26,27,29,30,33,48–51]
 40–44 4 (16) [17,18,25,28]
 Unspecified 2 (8) [19,20]
HPV testing
HPV specimen type
 Cervical cells 20 (80) [6,7,14,15,17,18,21,23–28,30,31,33,48–51]
 Biopsy 3 (12) [19,20,32]
 Cervical cells and/or biopsy 2 (8) [22,29]
HPV detection method
 PCR 21 (84) [6,7,14,15,18–23,26,27,29–33,48–51]
 Hybrid capture 2 4 (16) [17,24,25,28]
Pre-treatment HPV prevalencec,d
 Completely HPV negative 12 (48) [6,17,20–28,33]
 Mixed, incident type negative 15 (60) [6,7,14,15,19,20,22,23,27–30,33,48,49]
 Positive, incident type negative 15 (60) [6,7,18,20–23,28–33,50,51]
Treatment characteristics
Diagnostic method
 Histology 24 (96) [6,7,14,15,18–33,48–51]
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No. of studies (%) References
 Cytology 1 (4) [17]
Stage at treatmentc,e
 VIA positive 1 (4) [17]
 CIN 1 2 (8) [20,32]
 CIN 1/2 1 (4) [20]
 CIN 1/2/3 8 (32) [19,21,30–33,48,50]
 CIN 2 3 (12) [20,29,32]
 CIN 2/3 12 (48) [14,15,18,22,24–29,49,51]
 CIN 3 6 (24) [6,7,22,23,29,32]
Treatment type
 LEEPf 11 (44) [22–24,27–30,32,48,50,51]
 Laser conization 2 (8) [26,33]
 Laser ablation 1 (4) [20]
 Surgical conization 1 (4) [25]
 Cryotherapy 1 (4) [17]
 Alpha-interferon 1 (4) [19]
 Multiple treatment regimens 8 (32) [6,7,14,15,18,21,31,49]
HPV outcome ascertainment
Unit of analysis for incidence results
 Women 25 (100) [6,7,14,15,17–33,48–51]
HPV testing interval for first incident infection
 <6 months 14 (56) [6,7,19–24,26,27,29–31,48]
 6–12 months 8 (32) [14,17,18,25,28,32,50,51]
 >12 months 3 (12) [15,33,49]
Reported incident HPV types
 Any HPV 17 (68) [6,18,20–23,26–33,49–51]
 Specifically HR-HPV 7 (28) [7,14,15,17,24,25,48]
 Only HPV 6/16 1 (4) [19]
Abbreviations: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; HR-HPV, high-risk HPV; LEEP, loop electrical excision 
procedure; PCR, polymerase chain reaction; VIA, visual inspection with acetic acid.
a
Multi-region = Belgium and Nicaragua.
b
References [14,18] reported median age instead of mean age. For references [15,17], mean age was estimated from reported age distributions 
using the midpoint for each age category. Reference [29] did not report mean age, however this data was reported in a related publication [52].
c
A study can be listed in more than one category if they reported estimates for various patient subgroups, therefore the number of studies may sum 
to >100%.
d
Pre-treatment HPV prevalence refers to the prevalence of HPV infection within 6 months prior to or at the time of cervical treatment.
e
54% of women in Reference [20] had koilocytosis.
f
The LEEP category also includes studies that described treatment as large loop excision of the transformation zone (LLETZ) or diathermic large 
loop excision (DLLE); Reference [48] included one woman treated with cryotherapy.
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